Codiak BioSciences, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 7 rows in 2023. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2023-01-24: Reporting owner Konstantinov Konstantin; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-01-24: Reporting owner Mauro David J; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-01-24: Reporting owner Bain Linda; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2023-01-24: Reporting owner Sathyanarayanan Sriram; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2023-01-24 | Konstantinov Konstantin Officer (Chief Technology Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +145,000 145,000 owned after | $0.74 exercise price | 2023-01-26 | |
| 2023-01-24 | Mauro David J Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +190,000 190,000 owned after | $0.74 exercise price | 2023-01-26 | |
| 2023-01-24 | Bain Linda Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +185,000 185,000 owned after | $0.74 exercise price | 2023-01-26 | |
| 2023-01-24 | Sathyanarayanan Sriram Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +140,000 140,000 owned after | $0.74 exercise price | 2023-01-26 | |
| 2023-01-24 | Howze Yalonda Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $0.74 exercise price | 2023-01-26 | |
| 2023-01-24 | Barna Nicole Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +105,000 105,000 owned after | $0.74 exercise price | 2023-01-26 | |
| 2023-01-24 | WILLIAMS DOUGLAS E Director, Officer (President & CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +465,000 465,000 owned after | $0.74 exercise price | 2023-01-26 |